Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiomyopathy and Desmosomal Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DSP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DSP Recombinant Protein (N-terminal/C-terminal Domains) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View DSP Products |
| Gene Delivery | DSP Promise-ORF / Lentivirus Full-length ORF and clinical mutant variants for stable cell line construction. |
View DSP Products |
| Benchmark Ab | Anti-DSP Recombinant Antibody Recombinant positive control for IHC/WB/IF validation. |
View DSP Products |
| Validator | DSP siRNA Set For knockdown verification in cell-based junctional assays. |
View DSP Products |
| Related Target A | DSG2 (Desmoglein-2) Primary desmosomal cadherin; co-mutated or synergistic partner in arrhythmogenic cardiomyopathy. |
View DSG2 Products |
| Related Target B | PKP2 (Plakophilin-2) Key desmosomal plaque protein; essential for DSP recruitment and mechanical stability. |
View PKP2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Recapitulating Giant Structural Protein Expression | Lentivirus premade particles optimized for high-titer delivery of large DSP open reading frames. |
| Domain-Specific Interaction Screening | Truncated DSP domain proteins (Spectrin repeats, Plakin domains) strictly verified by theoretical MW and SDS-PAGE. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live DSP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DSP therapeutics is intensifying, with major players shifting focus from traditional symptom management to gene therapies and small molecules that stabilize desmosomal integrity. As first-generation gene replacement therapies reach preclinical and early clinical milestones, the next wave of R&D is targeting mutation-specific structural rescue and the prevention of fibrofatty remodeling in cardiac tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV/Lenti) | Tenaya Therapeutics, Rocket Pharmaceuticals | Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) | Transduction & expression validation (Need Lentivirus & Domain-specific Abs) |
| Small Molecule Stabilizers | Lexeo Therapeutics, Academic Spin-offs | Dilated Cardiomyopathy (DCM), Carvajal Syndrome | Protein-protein interaction assays (Need High-Purity Recombinant DSP Domains) |
| Monoclonal Antibodies | Autoimmune Researchers | Paraneoplastic Pemphigus (PNP) | Epitope mapping & autoantibody blocking (Need Sequence-Verified Antigens) |